Trial reportJournal of the American Society of Nephrology : JASN2011
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.
Trial report in Journal of the American Society of Nephrology : JASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Copeptin as a Biomarker in Chronic Kidney Disease-A Systematic Review and Meta-Analysis.Biomolecules · 2025Pooled it
- Copeptin as biomarker for acute ischemic stroke prognosis and revascularization treatment efficacy.Frontiers in neurology · 2024Pooled it
- Trial
- Recent approaches in the sensing strategy for the detection of cardiovascular disease biomarkers.RSC advances · 2026Review
- The relationship between serum copeptin levels, peritoneal transport parameters, and bioimpedance markers in pediatric patients undergoing peritoneal dialysis.Pediatric nephrology (Berlin, Germany) · 2026Article
- The Impact of Hydration on Metabolic Outcomes: From Arginine-Vasopressin Signaling to Clinical Implications.Medicina (Kaunas, Lithuania) · 2025Review
- Plasma copeptin and markers of arterial disorder in patients with type 2 diabetes, a cross-sectional study.Cardiovascular diabetology · 2024Article
- Copeptin, Natriuretic Peptides, and Cardiovascular Outcomes in Patients With CKD: The German Chronic Kidney Disease (GCKD) Study.Kidney medicine · 2023Article
- The role of copeptin in kidney disease.Endocrine · 2023Review
- Cardiorenal syndrome: Pathophysiology as a key to the therapeutic approach in an under-diagnosed disease.Journal of clinical ultrasound : JCU · 2022Review
- Physiological Mechanisms of Hypertension and Cardiovascular Disease in End-Stage Kidney Disease.Current hypertension reports · 2022Review
- Copeptin Concentrations in Plasma of Healthy Neonates in Relation to Water-Electrolyte Homeostasis in the Early Adaptation Period.Children (Basel, Switzerland) · 2022Article
- Clinical efficacy of biomarkers for evaluation of volume status in dialysis patients.Medicine · 2020Observational
- SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.Diabetes & metabolism · 2020Article
- Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.Disease markers · 2020 · on this mapReview
- Copeptin as a Biomarker of Atherosclerosis in Type 1 Diabetic Patients.Open access Macedonian journal of medical sciences · 2019Article
- Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes.Diabetes care · 2019Article
- Water intake keeps type 2 diabetes away? Focus on copeptin.Endocrine · 2018Review
- Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.Cardiovascular diabetology · 2018Observational
- Changes in Biomarker Profile and Left Ventricular Hypertrophy Regression: Results from the Frequent Hemodialysis Network Trials.American journal of nephrology · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In ESRD, the neurohormone arginine vasopressin (AVP) may act primarily through V1a and V1b receptors, which promote vasoconstriction, myocardial hypertrophy, and release of adrenocorticotropic hormone. The preanalytical instability of AVP limits the investigation of whether this hormone associates with cardiovascular events, but the stable glycopeptide copeptin may serve as a surrogate because it is co-secreted with AVP from the posterior pituitary. Here, we studied whether copeptin predicts cardiovascular risk and mortality in ESRD. We measured copeptin at baseline in 1241 hemodialysis patients with type 2 diabetes participating in the German Diabetes and Dialysis Study. The median copeptin level was 81 pmol/L (interquartile range, 81 to 122 pmol/L). In Cox regression analyses, compared with patients with copeptin levels in the lowest quartile (≤51 pmol/L), patients with copeptin levels in the highest quartile (>122 pmol/L) had a 3.5-fold increased risk for stroke (HR, 3.48; 95% CI: 1.71 to 7.09), a 73% higher risk for sudden death (HR, 1.73; 95% CI: 1.01 to 2.95), a 42% higher risk for combined cardiovascular events (HR, 1.42; 95% CI: 1.06 to 1.90), and a 48% higher risk for all-cause mortality (HR, 1.48; 95% CI: 1.15 to 1.90). In contrast, we did not detect significant associations between copeptin levels and risks for myocardial infarction or death caused by congestive heart failure. In conclusion, copeptin levels strongly associate with stroke, sudden death, combined cardiovascular events, and mortality in hemodialysis patients with type 2 diabetes. Whether vasopressin receptor antagonists will improve these outcomes requires further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.